The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy

We herein report the cytokine expression at different stages for three patients who developed cardiac complications after immune checkpoint inhibitor (ICI) therapy. Case 1 with biopsy-proven myocarditis showed increased levels of interleukin (IL)-8, monocyte chemotactic and activating factor, and gr...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2021/02/01, Vol.60(3), pp.423-429
Main Authors: Tsuruda, Toshihiro, Yoshikawa, Naoki, Kai, Motoaki, Yamaguchi, Masashi, Toida, Reiko, Kodama, Tsuyoshi, Kajihara, Kei, Kawabata, Takayuki, Nakamura, Takeshi, Sakata, Koji, Hatakeyama, Kinta, Gi, Toshihiro, Asada, Yujiro, Tono, Tetsuya, Kitamura, Kazuo, Ikeda, Ryuji
Format: Article
Language:English
Subjects:
Biopsy
cancer
Cardiomyopathy
Case Report
Colony-stimulating factor
cytokine releasing syndrome
Cytokines
Granulocyte-Macrophage Colony-Stimulating Factor
Heart diseases
Humans
Immune Checkpoint Inhibitors
Interferon-gamma
Interleukin 6
Interleukin 8
Internal medicine
Male
Monocyte chemoattractant protein 1
Monocytes
Myocarditis
troponin
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We herein report the cytokine expression at different stages for three patients who developed cardiac complications after immune checkpoint inhibitor (ICI) therapy. Case 1 with biopsy-proven myocarditis showed increased levels of interleukin (IL)-8, monocyte chemotactic and activating factor, and granulocyte macrophage colony-stimulating factor (GM-CSF) when he developed Takotsubo cardiomyopathy. Case 2 with subclinical myocarditis showed predominant activation of IL-8 during the progressive clinical course. Case 3 with cytokine-releasing syndrome showed substantial activations of IL-6, IL-8, GM-CSF, and interferon-γ. Our data suggest the development of unique cytokine activation in individual patients with cardiac complications after ICI therapy.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.5317-20